Latest news with #RizwanSuliankatchiAbdulkader
The Hindu
7 hours ago
- Health
- The Hindu
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. "But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment," Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India," said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. "We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed," said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. "India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care," Rizwan said.
The Print
a day ago
- Health
- The Print
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. New Delhi, Jul 12 (PTI) People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. 'But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment,' Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India,' said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. 'We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed,' said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. 'India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care,' Rizwan said. PTI PLB SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
The Hindu
4 days ago
- Health
- The Hindu
ICMR-NIE study calls for year-round monitoring of respiratory infections
Researchers at the ICMR's National Institute of Epidemiology (NIE) in Chennai have highlighted the need for year-round and integrated surveillance of severe acute respiratory infections and influenza-like illness, which are potential threats to public health, to detect early warnings. Study findings This comes in the view of a new public health study, published in 'Discover Health Systems' journal last month, which has revealed key insights into how Tamil Nadu monitors and responds to cases of influenza-like illness (ILI) and severe acute respiratory infections (SARI). The study found that surveillance efforts are stepped up only during outbreaks or specific seasons, even though respiratory viruses circulate throughout the year. The study evaluated the functioning of disease surveillance systems in four districts of the state from 2023 to 2024. Engaging more than 370 stakeholders across 85 healthcare facilities and 23 laboratories, the study found that while Tamil Nadu has built a foundation for respiratory illness surveillance, further improvements are needed to make the system more consistent, routine, and capable of responding to emerging public health threats. "This is the first study of its kind in India that provides evidence-based recommendations to strengthen disease surveillance at all levels," said Dr Rizwan Suliankatchi Abdulkader, the principal investigator of the study, ICMR-NIE. "Tamil Nadu has made significant strides in health surveillance. This report reinforces the importance of year-round, integrated disease monitoring to protect public health," said Dr T S Selva Vinayagam, director of public health and preventive medicine, the Government of Tamil Nadu. The study stated that more than half of the facilities surveyed had systems in place to report ILI/SARI cases, but only 42 per cent regularly collected clinical samples for testing. Besides, relatively few medical personnel had received specific training in identifying and reporting such cases. Need for improved surveillance Testing facilities were mostly concentrated in larger hospitals, with primary and secondary care facilities lacking necessary equipment and resources to conduct tests, Dr Rizwan said. While public health centres widely used the Integrated Health Information Platform (IHIP), the system faced challenges such as inconsistent data entry, multiple overlapping reporting formats, and minimal participation from private hospitals and labs. "The study also noted that surveillance efforts tend to intensify only during outbreaks or specific seasons, even though respiratory viruses circulate throughout the year," Dr Rizwan said. Influenza surveillance remains a seasonal event in Tamil Nadu, the study noted. "With changing ecological conditions, efforts should be made to ensure year-round reporting of cases. Testing for influenza should be prioritised and infrastructure and testing for novel pathogens should be developed," it said. Although guidelines are in place, a gap still exists in awareness amongst the health workers, especially community health workers regarding the importance of influenza surveillance. Structured training should be provided for trainers and there should be mechanisms for regular training of community health workers. Frequent monitoring should be employed and structured feedback should be provided to ensure complete and accurate data for a better understanding of the disease trends. Involvement of the private sector in surveillance activities is evident but partial, the study said. One health approach A 'One Health' approach should be adopted involving other sectors and data-sharing mechanisms should be in place ensuring transparency of data. With the plans already being discussed by the state, we may expect an improvement in surveillance standards for influenza soon, the study said. Surveillance is the key to identifying and detecting health events in the community and it provides the scientific and factual evidence essential for informed decision-making and appropriate public health action, the study found. Study participants identified several measures to improve surveillance, which included scaling up training for healthcare workers and community-level providers, improving digital infrastructure and mobile access to reporting platforms, expanding participation from private hospitals and diagnostic labs and engaging wide range of health workers such as mid-level providers and community volunteers. Tamil Nadu has already taken steps such as introducing the Laboratory Information Management System (LIMS) to streamline sample collection and transport. Plans are also in place to establish a "One Health" secretariat aimed at improving inter-departmental coordination and surveillance of zoonotic diseases, Dr Manoj Murhekar, director of NIE said. These initiatives could boost the state's ability to track influenza and other respiratory threats more effectively, he said. The researchers recommended transitioning from seasonal to continuous surveillance of ILI/SARI. They also suggested boosting laboratory capacity and resources across all levels of care, offering regular refresher training to healthcare providers and establishing structured feedback loops and monitoring systems to improve data quality and reporting accuracy and conducting similar situation analyses across the country. The study was supported by the Department of Health Research, Ministry of Health and Family Welfare, Government of India. The findings aim to guide state-level policy and improve the preparedness for respiratory disease outbreaks, including potential pandemics, said Dr Murhekar. Respiratory infections are a major contributor to morbidity and mortality. Globally, in 2021, an estimated 2.18 million deaths occurred due to lower respiratory tract infections (LRI), the study mentioned. Influenza viruses were responsible for more than five million hospitalisations. The Global Burden of Disease study has estimated 98,200 deaths due to influenza globally in 2021. Thirty-six per cent of worldwide deaths due to influenza occur in low and middle-income countries (LMICs). Influenza-associated mortality in India is higher among adults aged 65 years and above and children below five years. The Southeast Asia (SEA) region is considered a 'hotspot' for emerging and re-emerging infectious diseases, especially those with pandemic potential. The region has witnessed a significant increase in pandemic and epidemic-prone diseases in the last decade such as Severe Acute Respiratory Syndrome Coronavirus Infection (2002-2004), Influenza A H1N1 2009 (Swine Flu), Middle East Respiratory Syndrome (MERS) infection (2012), and COVID-19 (2020-2023) that have resulted in high morbidity and mortality.
Time of India
4 days ago
- Health
- Time of India
ICMR-NIE study calls for year-round monitoring of respiratory infections
New Delhi: Researchers at the ICMR 's National Institute of Epidemiology ( NIE ) in Chennai have highlighted the need for year-round and integrated surveillance of severe acute respiratory infections and influenza-like illness, which are potential threats to public health, to detect early warnings. This comes in the view of a new public health study, published in 'Discover Health Systems' journal last month, which has revealed key insights into how Tamil Nadu monitors and responds to cases of influenza-like illness (ILI) and severe acute respiratory infections (SARI). The study found that surveillance efforts are stepped up only during outbreaks or specific seasons, even though respiratory viruses circulate throughout the year. The study evaluated the functioning of disease surveillance systems in four districts of the state from 2023 to 2024. Engaging more than 370 stakeholders across 85 healthcare facilities and 23 laboratories, the study found that while Tamil Nadu has built a foundation for respiratory illness surveillance, further improvements are needed to make the system more consistent, routine, and capable of responding to emerging public health threats. "This is the first study of its kind in India that provides evidence-based recommendations to strengthen disease surveillance at all levels," said Dr Rizwan Suliankatchi Abdulkader, the principal investigator of the study, ICMR-NIE. "Tamil Nadu has made significant strides in health surveillance. This report reinforces the importance of year-round, integrated disease monitoring to protect public health," said Dr T S Selva Vinayagam , director of public health and preventive medicine, the Government of Tamil Nadu. The study stated that more than half of the facilities surveyed had systems in place to report ILI/SARI cases, but only 42 per cent regularly collected clinical samples for testing. Besides, relatively few medical personnel had received specific training in identifying and reporting such cases. Testing facilities were mostly concentrated in larger hospitals, with primary and secondary care facilities lacking necessary equipment and resources to conduct tests, Dr Rizwan said. While public health centres widely used the Integrated Health Information Platform (IHIP), the system faced challenges such as inconsistent data entry, multiple overlapping reporting formats, and minimal participation from private hospitals and labs. "The study also noted that surveillance efforts tend to intensify only during outbreaks or specific seasons, even though respiratory viruses circulate throughout the year," Dr Rizwan said. Influenza surveillance remains a seasonal event in Tamil Nadu, the study noted. "With changing ecological conditions, efforts should be made to ensure year-round reporting of cases. Testing for influenza should be prioritised and infrastructure and testing for novel pathogens should be developed," it said. Although guidelines are in place, a gap still exists in awareness amongst the health workers, especially community health workers regarding the importance of influenza surveillance. Structured training should be provided for trainers and there should be mechanisms for regular training of community health workers. Frequent monitoring should be employed and structured feedback should be provided to ensure complete and accurate data for a better understanding of the disease trends. Involvement of the private sector in surveillance activities is evident but partial, the study said. A 'One Health' approach should be adopted involving other sectors and data-sharing mechanisms should be in place ensuring transparency of data. With the plans already being discussed by the state, we may expect an improvement in surveillance standards for influenza soon, the study said. Surveillance is the key to identifying and detecting health events in the community and it provides the scientific and factual evidence essential for informed decision-making and appropriate public health action, the study found. Study participants identified several measures to improve surveillance, which included scaling up training for healthcare workers and community-level providers, improving digital infrastructure and mobile access to reporting platforms, expanding participation from private hospitals and diagnostic labs and engaging wide range of health workers such as mid-level providers and community volunteers. Tamil Nadu has already taken steps such as introducing the Laboratory Information Management System (LIMS) to streamline sample collection and transport. Plans are also in place to establish a "One Health" secretariat aimed at improving inter-departmental coordination and surveillance of zoonotic diseases, Dr Manoj Murhekar , director of NIE said. These initiatives could boost the state's ability to track influenza and other respiratory threats more effectively, he said. The researchers recommended transitioning from seasonal to continuous surveillance of ILI/SARI. They also suggested boosting laboratory capacity and resources across all levels of care, offering regular refresher training to healthcare providers and establishing structured feedback loops and monitoring systems to improve data quality and reporting accuracy and conducting similar situation analyses across the country. The study was supported by the Department of Health Research, Ministry of Health and Family Welfare, Government of India. The findings aim to guide state-level policy and improve the preparedness for respiratory disease outbreaks, including potential pandemics, said Dr Murhekar. Respiratory infections are a major contributor to morbidity and mortality. Globally, in 2021, an estimated 2.18 million deaths occurred due to lower respiratory tract infections (LRI), the study mentioned. Influenza viruses were responsible for more than five million hospitalisations. The Global Burden of Disease study has estimated 98,200 deaths due to influenza globally in 2021. Thirty-six per cent of worldwide deaths due to influenza occur in low and middle-income countries (LMICs). Influenza-associated mortality in India is higher among adults aged 65 years and above and children below five years. The Southeast Asia (SEA) region is considered a 'hotspot' for emerging and re-emerging infectious diseases, especially those with pandemic potential. The region has witnessed a significant increase in pandemic and epidemic-prone diseases in the last decade such as Severe Acute Respiratory Syndrome Coronavirus Infection (2002- 2004), Influenza A H1N1 2009 ( Swine Flu ), Middle East Respiratory Syndrome (MERS) infection (2012), and COVID-19 (2020- 2023) that have resulted in high morbidity and mortality.
